|
|
|
| Efficacy of venlafaxine on prophylaxis and treatment of different TCM syndrome types of major depressive disorder |
| LIU Lan-ying*, LUO Li-yuan, ZHU Chun-qing, WANG Pei-rong, YANG Chun-yu, NING Fang
|
| *Department of Mental Health,Tongde Hospital of Zhejiang Province,Hangzhou,Zhejiang 310012,China |
|
|
|
|
Abstract Objective To explore the efficacy of venlafaxine in prophylaxis and treatment of different TCM syndrome types of major depressive disorder. Methods From January 2015 to May 2017,thirty stagnation of liver-qi type and twenty-five insufficiency of heart and spleen type of patients with depression were recruited and treated by venlafaxine. The treatment course was six weeks. The efficacy was evaluated by Hamilton Depression Scale（HAMD）and Rating Scale for Side Effects（SERS）. Results There were no statistically significant differences in age,gender,education,family history,course of the disease and HAMD at baseline between the stagnation of liver-qi type group and the insufficiency of heart and spleen type group（P>0.05）. The HAMD scores of the two groups were significantly decreased at two,four,six weeks after venlafaxine treatment;the HAMD scores of stagnation of liver-qi type group were significantly lower than that of insufficiency of heart and spleen type group at the second week,the fourth week and the sixth week（all P<0.001）. After six weeks of treatment,the scores of anxiety or somatization,cognitive impairment,retardation and hopelessness factors decreased more in the stagnation of liver-qi type group than that in the insufficiency of heart and spleen type group（P<0.05）. The scores of SERS have no statistically significant difference between the two groups（3.60±4.98 vs.3.16±2.93）（P>0.05）. Conclusion Venlafaxine has some treatment effect both on the stagnation of liver-qi type and the insufficiency of heart and spleen type of patients with depression,but better in the stagnation of liver-qi type.
|
|
Received: 20 October 2017
Revised: 27 January 2018
Published: 22 May 2018
|
|
|
|
|
|
[1] 林上统,何凡,翟羽佳,等. 农民居民抑郁及影响因素分析[J]. 预防医学,2017,29(9):922-925.
[2] 王俊霞,张德勇,叶建武,等. 莲都区中学生抑郁症状现状调查[J]. 浙江预防医学,2016,28(2):160-161.
[3] 王旭东,乔明琦,张樟进,等. 中医药治疗抑郁症研究进展[J]. 南京中医药大学学报,2016,32(1):93-96.
[4] MIRET M,AYUSO-MATEOS J L,SANCHEZ-MORENO J,et al. Depressive disorders and suicide:Epidemiology,risk factors,and burden[J]. Neurosci Biobehav Rev,2013,37(10):2372-2374.
[5] KESSLER R C,BROMET E J.The epidemiology of depression across cultures[J]. Annu Rev Public Health,2013,34:119-138.
[6] 王小青. 100例抑郁症中医病因病机的临床研究[D]. 武汉:湖北中医药大学,2012.
[7] 李惠春. 抑郁症的个体化治疗与药物选择[J]. 中华精神科杂志,2013,46(4):246-247.
[8] 王刚,马辛. 抑郁症未来的研究方向[J]. 中华精神科杂志,2013,46(2):117-118.
[9] 李红兵,谭子虎. 神经重构与抑郁症[J]. 中华行为医学与脑科学杂志,2016,25(12):1142-1146.
[10] 曲万仁,付建国. 文拉法辛对抑郁症患者神经递质及细胞因子表达的影响[J]. 中国实用神经疾病杂志,2016,19(4):29-30.
[11] 唐启盛. 抑郁症:中西医基础与临床[M]. 北京:中国中医药出版社,2006.
[12] 周仲瑛. 中医内科学[M]. 北京:中国中医药出版社,2007, 376-378.
[13] FU C H,STEINER H,COSTAFREDA S G.Predictive neural biomarkers of clinical response in depression:A meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies[J]. Neurobiology of Disease,2013,52:75-83.
[14] MOYLAN S,MAES M,WRAY N R,et al.The neuroprogressive nature of major depressive disorder:pathways to disease evolution and resistance,and therapeutic implications[J]. Mol Psychiatry,2013,18(5):595-606.
[15] VON WOLFF A,HÖLZEL L P,WESTPHAL A,et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia:a systematic review and meta-analysis[J]. Journal of Affective Disorders,2013,144(1):7-15.
[16] 杨慧敏,李跃华,杨京,等. 抑郁症中医辨证分型与外周血神经递质的关系[J]. 中国中医药信息杂志,2011,18(4):14-16.
[17] 吴文源,黄继忠,司天梅,等. 文拉法辛缓释剂临床应用专家指导建议[J]. 中国心理卫生杂志,2013,27(7):550-560.
[18] 徐维尧,韩金会. 文拉法辛缓释片治疗广泛性焦虑症的临床疗效及安全性分析[J]. 中国实用神经疾病杂志,2017,20(10):117-119.
[19] 高之涵,朱建峰,沈莹,等. 肝郁气滞与心脾两虚抑郁症HPA轴及精神病理学差异分析[J]. 浙江中医杂志,2017,52(5):324-324. |
|
|
|
